Today, just over two weeks from the launch of the Open Pharma position statement on open access, we reflect on how the statement came about, the benefits it offers to different types of stakeholders and the success it has had so far.
Last week was International Open Access Week covering the topic ‘Open for whom? Equity in open knowledge’. Open Pharma kicked off this year’s Open Access Week with the launch of its position statement on open access at a MedComms Networking event in Oxford on 21 October 2019. The statement calls for publishers to allow authors … Continue reading Find out what Open Pharma achieved during Open Access Week 2019
ORCID is part of the wider digital infrastructure needed for researchers to share information on a global scale. ORCID enables transparent and trustworthy connections between researchers, their contributions, and affiliations by providing an identifier for individuals to use with their name as they engage in research, scholarship and innovation activities. The Open Pharma community is … Continue reading Guest post: ORCID adoption in the pharma community
Finding a good book to read on holiday may sometimes be a challenge. Luckily, the Open Pharma team is here to help with its shortlist of the best reads for summer 2019!
The Association of the British Pharmaceutical Industry (ABPI) has said that it wants to take transparency to the next level, and has committed to making clinical research more accessible and understandable across the pharmaceutical industry.
Evidence is essential for identifying treatment priorities and developing polices, said Claire Allen of Evidence Aid, at Evidence-Based Medicine Live (EBMLive), which took place on 15–17 July in Oxford, UK.
At a workshop on managing conflicts of interest in medicine, Chris Winchester, CEO of Oxford PharmaGenesis and co-founder of Open Pharma, argued for openness.
When it comes to driving change in academic publishing practices, much of the focus is on making research outputs freely available to all those who wish to access them. However, open access publishing is just the tip of the iceberg.
On 11–12 June 2019, over 60 pharma stakeholders met in Amsterdam at the 8th Annual Publication and Clinical Trial Transparency Conference to discuss the evolving landscape of clinical trial transparency.
The Good Practice for Conference Abstracts and Presentations (GPCAP) recommendations have been developed to address the challenges faced by industry professionals and authors when preparing abstracts and presentations for academic conferences.